⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
MitoQ (Mitoquinone)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-05 — Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans: Separate placebo-controlled RCT (n=56/group, 20 mg/day oral MitoQ for 3 months) in adults ≥60 testing endothelial function and aortic stiffness endpoints, building on prior mouse restoration data and a small human pilot — protocol/confirmatory design, no readout yet. [human-rct] (novelty: 3)
- 2026-08-12 — The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults: Mito-Frail trial registered/launched: early-phase interventional protocol testing MitoQ vs placebo in frail older adults with vascular (central and cerebral vasodilation), oxidative stress, mobility, and cognitive endpoints — protocol/aims only, no readout yet. [human-rct] (novelty: 3)
Open questions
Related
Contributing findings
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
12-aug-2026
novelty 3
per-area 3
strengthens
Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans
05-aug-2026
novelty 3
per-area 3
strengthens